Reuters – Pfizer announces positive topline results of COVID-19 vaccine study in adolescents

Pfizer-BioNTech announced on Wednesday that their COVID-19 demonstrated 100% efficacy and robust antibody responses in participants aged 12-15 years old, as reported by Reuters.

“Companies plan to submit these data to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as soon as possible to request expansion of emergency use authorization,” Reuters further noted.